Pages that link to "Q39932245"
Jump to navigation
Jump to search
The following pages link to Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial (Q39932245):
Displaying 50 items.
- Natural Killer Cells for Therapy of Leukemia (Q26745906) (← links)
- Natural Killer Cells for Immunotherapy - Advantages of the NK-92 Cell Line over Blood NK Cells (Q26751020) (← links)
- Natural Killer Cell Recognition of Melanoma: New Clues for a More Effective Immunotherapy (Q26771449) (← links)
- Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity (Q26773135) (← links)
- Selection and expansion of natural killer cells for NK cell-based immunotherapy (Q26774777) (← links)
- Strategies for combining immunotherapy with radiation for anticancer therapy (Q26796675) (← links)
- NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy (Q26797345) (← links)
- Natural killer cell biology: an update and future directions (Q26830512) (← links)
- Advantages and clinical applications of natural killer cells in cancer immunotherapy (Q26999224) (← links)
- In vivo monitoring of natural killer cell trafficking during tumor immunotherapy (Q27011245) (← links)
- Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor (Q27318470) (← links)
- High log-scale expansion of functional human natural killer cells from umbilical cord blood CD34-positive cells for adoptive cancer immunotherapy (Q27334458) (← links)
- Natural killer cells in human cancer: from biological functions to clinical applications (Q27691427) (← links)
- Manufacturing Natural Killer Cells as Medicinal Products (Q28069992) (← links)
- Understanding of molecular mechanisms in natural killer cell therapy (Q28086976) (← links)
- Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer (Q28266580) (← links)
- Focused ultrasound delivers targeted immune cells to metastatic brain tumors (Q30441716) (← links)
- Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity (Q33700795) (← links)
- NK cell-based immunotherapy for malignant diseases (Q33827433) (← links)
- Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor (Q34042430) (← links)
- Natural killer cells for cancer immunotherapy: pluripotent stem cells-derived NK cells as an immunotherapeutic perspective (Q34180695) (← links)
- Opportunities and limitations of natural killer cells as adoptive therapy for malignant disease (Q34307792) (← links)
- GMP-compliant, large-scale expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells in vitro and in vivo (Q34551581) (← links)
- Low-dose ionizing radiation induces direct activation of natural killer cells and provides a novel approach for adoptive cellular immunotherapy (Q34712771) (← links)
- Adoptive Transfer of Autologous Natural Killer Cells Leads to High Levels of Circulating Natural Killer Cells but Does Not Mediate Tumor Regression (Q35269067) (← links)
- CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells. (Q35834087) (← links)
- Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer (Q36055257) (← links)
- Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model. (Q36094697) (← links)
- Treatment of a solid tumor using engineered drug-resistant immunocompetent cells and cytotoxic chemotherapy (Q36114222) (← links)
- Potential Use of Natural Killer Cell Transfer Therapy in the Perioperative Period to Improve Oncologic Outcomes (Q36245682) (← links)
- Comparison of mRNA and lentiviral based transfection of natural killer cells with chimeric antigen receptors recognizing lymphoid antigens (Q36377047) (← links)
- Autologous stem cell transplant recipients tolerate haploidentical related-donor natural killer cell-enriched infusions (Q36546883) (← links)
- Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications (Q36676064) (← links)
- Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival (Q36821054) (← links)
- (19)F-MRI for monitoring human NK cells in vivo (Q37012655) (← links)
- Ex vivo generation of highly purified and activated natural killer cells from human peripheral blood (Q37122377) (← links)
- A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer (Q37141237) (← links)
- Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity (Q37434670) (← links)
- New frontiers in cell-based immunotherapy of cancer. (Q37481361) (← links)
- An allogeneic NK cell line engineered to express chimeric antigen receptors: A novel strategy of cellular immunotherapy against cancer (Q37488222) (← links)
- CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma (Q37666309) (← links)
- An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele (Q37686302) (← links)
- Use of allogeneic NK cells for cancer immunotherapy. (Q37957140) (← links)
- Targeting natural killer cells and natural killer T cells in cancer (Q37995950) (← links)
- Natural killer cell lines in tumor immunotherapy (Q37998371) (← links)
- Natural killer cells: a review of manufacturing and clinical utility. (Q38016470) (← links)
- Generation of natural killer cells from hematopoietic stem cells in vitro for immunotherapy (Q38019320) (← links)
- The TNF receptor-ligands 4-1BB-4-1BBL and GITR-GITRL in NK cell responses (Q38073762) (← links)
- Hunting for clinical translation with innate-like immune cells and their receptors (Q38171917) (← links)
- Clinical utility of natural killer cells in cancer therapy and transplantation (Q38195120) (← links)